Needham & Company LLC Reiterates Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reissued by stock analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports. They presently have a $6.00 target price on the stock. Needham & Company LLC’s price objective indicates a potential upside of 219.15% from the stock’s current price.

Several other equities research analysts have also issued reports on the stock. Canaccord Genuity Group raised their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Chardan Capital reissued a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA opened at $1.88 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The stock’s fifty day moving average is $2.10 and its 200 day moving average is $2.14. The firm has a market capitalization of $385.29 million, a PE ratio of 2.98 and a beta of 0.95. Taysha Gene Therapies has a fifty-two week low of $1.19 and a fifty-two week high of $4.32.

Institutional Investors Weigh In On Taysha Gene Therapies

Several hedge funds have recently made changes to their positions in TSHA. Wellington Management Group LLP purchased a new position in shares of Taysha Gene Therapies in the 3rd quarter worth approximately $931,000. Charles Schwab Investment Management Inc. lifted its position in Taysha Gene Therapies by 7.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock valued at $930,000 after purchasing an additional 33,123 shares during the period. Geode Capital Management LLC boosted its holdings in Taysha Gene Therapies by 23.7% in the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock valued at $7,163,000 after purchasing an additional 682,273 shares during the last quarter. Barclays PLC grew its position in Taysha Gene Therapies by 356.0% during the 3rd quarter. Barclays PLC now owns 247,280 shares of the company’s stock worth $513,000 after purchasing an additional 193,046 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at about $1,018,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.